Why documentation review comes first for pain practices
Pain management and physical medicine groups tend to scrutinize biologics suppliers closely, given how closely regulators have watched the exosome and cord-tissue category. Before placing an order, most practices request the processing description, sterility testing summary and lot-specific certificate of analysis for any product under consideration.
For exosome products specifically, it is worth confirming directly with any supplier that no exosome product currently carries FDA approval, and that exosome preparations are generally regulated as biologic drugs rather than as minimally manipulated tissue. Precision Biologics states this plainly rather than leaving it implied.
Youngstown
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
18- Pain Medicine
- 12
- Physical Medicine & Rehabilitation
- 6
Account verification and ordering
A National Provider Identifier is required to open an account, and we verify it against the NPPES registry before any order ships. This applies the same way to a solo pain management physician as it does to a multi-provider physical medicine group.
Each shipment carries a unique lot identifier so the practice can maintain its own patient-level record of which lot was used, supporting internal traceability independent of anything Precision Biologics tracks.
Receiving shipments in the Midwest
Wharton's jelly products that ship cryopreserved travel overnight on dry ice in validated containers and are stored at -80 degrees Celsius on arrival; practices need staff available to move product into ultra-low freezer storage promptly on delivery days. Lyophilized exosome formats are shelf-stable and do not require that same receiving coordination.
Oversight and getting set up
Whether a given use of a Wharton's jelly or exosome product fits within a practice's regulatory posture is a determination for the practice, its medical director and its own legal counsel, not something a distributor can resolve. We encourage pain management practices to confirm their own standing with the Ohio medical board as part of that review.
Setting up an account starts with NPI and license verification; once confirmed, we share the documentation set for each product line and can arrange a peer-to-peer call focused on paperwork, not treatment decisions.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Is Bio Xsomes or another exosome product FDA approved for pain management practices in Youngstown?+
No exosome product is FDA approved. Bio Xsomes, Bio EX and Bio AER are supplied with characterization and ingredient documentation for licensed practices to evaluate; purchase and use decisions rest with the practice and its own regulatory counsel.
What should a Youngstown pain practice ask for before its first order?+
Request the certificate of analysis, the donor eligibility summary for Wharton's jelly products, or the full ingredient disclosure for exosome products, and confirm your account is NPI-verified before product ships.
Does Precision Biologics advise on dosing or injection protocols?+
No. We supply product and documentation only. Clinical decisions, including dosing and technique, are made by the treating physician in consultation with their own training and counsel.